肿瘤微管介导胶质瘤对手术损伤和化疗的抵抗
研究将患者来源的胶质母细胞瘤干细胞样细胞植入小鼠颅窗,用活体双光子显微镜长期追踪。结果发现手术损伤后肿瘤细胞向损伤区延伸肿瘤微管并过度再填充,抑制肿瘤微管可阻断该反应,而地塞米松无效;肿瘤细胞整合入肿瘤微管网络后更易抵抗替莫唑胺化疗。
要点
- 胶质瘤细胞通过肿瘤微管向手术损伤区延伸,导致肿瘤细胞密度显著超过未损伤脑区。
- 靶向生长相关蛋白-43抑制肿瘤微管形成与功能,可阻断手术诱导的肿瘤生长反应,而地塞米松无效。
- 肿瘤细胞整合入肿瘤微管网络后更易抵抗替莫唑胺化疗,肿瘤微管形成与连接的瘤内和瘤间异质性与治疗反应强相关。
核心结论
- 肿瘤微管可介导胶质瘤对手术和化疗等标准治疗模式的抵抗。
- 特异性抑制肿瘤微管是减少术后局部复发和降低化疗抵抗的有前景的方法。
研究设计与样本
- 将患者来源的胶质母细胞瘤干细胞样细胞系植入小鼠颅窗下。
- 采用纵向活体双光子激光扫描显微镜追踪肿瘤生长及单个胶质瘤细胞命运达数月。
主要发现
- 圆柱形手术损伤后,胶质母细胞瘤干细胞样细胞越来越多地向损伤区延伸肿瘤微管,并在数周内参与该区域再填充。
- 观察到过度愈合反应,随时间推移肿瘤细胞密度显著超过未损伤脑区。
- 通过靶向生长相关蛋白-43的遗传学方法抑制肿瘤微管形成和功能,稳健抑制了手术诱导的肿瘤生长反应,而术后标准抗炎治疗地塞米松无此作用。
- 一个周期替莫唑胺化疗后,肿瘤微管形成与连接的瘤内和瘤间异质性与治疗反应强相关:肿瘤细胞整合入肿瘤微管网络时更可能抵抗化疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary and adaptive resistance against chemo- and radiotherapy and local recurrence after surgery limit the benefits from these standard treatments in glioma patients. Recently we found that glioma cells can extend ultra-long membrane protrusions, "tumor microtubes" (TMs), for brain invasion, proliferation, and interconnection of single cells to a syncytium that is resistant to radiotherapy. We wondered whether TMs also convey resistance to the other 2 standard treatment modalities. METHODS: Patient-derived glioblastoma stemlike cell (GBMSC) lines were implanted under a cranial window in mice. Longitudinal in vivo two-photon laser scanning microscopy was used to follow tumor growth, including the fate of single glioma cells over months. RESULTS: After a cylindrical surgical lesion, GBMSCs increasingly extended TMs toward the lesion area, which contributed to the repopulation of this area over many weeks. In fact, an excessive "healing response" was observed in which tumor cell densities significantly exceeded those of unlesioned brain regions over time. Inhibition of TM formation and function by genetic targeting of growth associated protein-43 robustly suppressed this surgery-induced tumor growth reaction, in contrast to standard postsurgical anti-inflammatory treatment with dexamethasone. After one cycle of temozolomide chemotherapy, intra- and intertumoral heterogeneity of TM formation and interconnection was strongly associated with therapy response: when tumor cells were integrated in TM networks, they were more likely to resist chemotherapy. CONCLUSION: TMs can contribute to the resistance against standard treatment modalities in gliomas. Specific inhibition of TMs is a promising approach to reduce local recurrence after surgery and lower resistance to chemotherapy.
引用
- Weil S, Osswald M, Solecki G, et al. Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas. Neuro Oncol. 2017. PMID: 28419303. doi:10.1093/neuonc/nox070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。